Outcomes | Number of passes | Unadjusted analyses | Pre-specified adjusted analyses* | |||
≤3 (n=212) | >3 (n=69) | OR (95% CI) | P values | OR (95% CI) | P values | |
Favorable outcome | 118/206 (57.3) | 25/64 (39.1) | 0.48 (0.26 to 0.85) | 0.012 | 0.64 (0.29 to 1.43) | 0.27 |
90-day mRS† | 2 (1 to 4) | 3 (1 to 5) | 0.53 (0.32 to 0.87) | 0.011 | 0.73 (0.41 to 1.29) | 0.27 |
Any ICH | 88/207 (42.5) | 43/69 (62.3) | 2.24 (1.27 to 3.93) | 0.005 | 1.75 (0.91 to 3.36) | 0.096 |
Parenchymal hematoma | 21/207 (10.1) | 21/69 (30.4) | 3.88 (1.95 to 7.70) | 0.001 | 3.62 (1.55 to 8.44) | 0.003 |
Subarachnoid hemorrhage | 13/207 (6.3) | 6/69 (8.7) | 1.42 (0.51 to 3.92) | 0.40 | NA | |
90-day mortality | 30/206 (14.6) | 12/64 (18.8) | 1.36 (0.64 to 2.84) | 0.42 | 0.74 (0.27 to 2.05) | 0.57 |
Values expressed as no./total no. (%) or median (IQR)
*calculated using a mixed (binary or ordinal) logistic regression model including center as random effect, first-line thrombectomy device, age, admission NIHSS, ASPECTS, pre-stroke mRS ≥1, intravenous rt-PA, onset to recanalization time and mTICI grades (2b vs 2 c/3).
†shift-analysis (OR per 1 point-improvement in mRS)
ASPECTS, Alberta stroke program early CT score; ICH, intracerebral hemorrhage; mRS, modified Rankin scale; mTICI, modified treatment in cerebral infarction score; NA, not applicable; NIHSS, National Institute of Health Stroke Scale; OR, OR ratio; rt-PA, recombinant tissue plasminogen activator.